-
.jpg)
.jpg)
- SITC 2024_CAR-T POSTER
- GI-101A, a Novel CD80-IgG4-IL2v2 Fusion Protein, Promotes CAR-T Expansion and Enhances Anticancer Potential by Increasing Memory T Cell Population in a Lymphoma Model
-
.jpg)
- SITC 2023_GI-102 POSTER
- GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocytes expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
-
.jpg)
.jpg)
- 2023 SITC_GI-108 POSTER
- GI-108, a novel anti-CD73-IL2v bispecific fusion protein augments anti-tumor immunity by alleviating immunosuppressive adenosine pathway in CD8+ T cells
-
.jpg)
.jpg)
- SITC 2022 POSTER
- Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent andin combination with pembrolizumab in patients with advanced and/or metastatic solid tumors
-
.jpg)
.png)
- Participate in ASCO 2022
-
.jpg)
.jpg)
- Korea excellent patent grand prize
-
(1).jpg)
.jpg)
- Certificate of IP Management Enterprise
- Korean Intellectual Property Office
-
.jpg)
.jpg)
- Certificate of Excellent Enterprise for Employee's Invention Compensation
- Korean Intellectual Property Office
-
.jpg)
.jpg)
- Selection Top 100 National R&D performances in 2020
- GI-101, Selection Top 100 National R&D performances in 2020 from Ministry of Science and ICT
-
.jpg)
.jpg)
- Korea Bio pharmaceuticals award
- Awardee of 'Global Challenger' in Korea Bio pharmaceuticals (GI-301)